Board MeetingMay 14, 2026, 08:32 AM
Milestone Pharma to Present at H.C. Wainwright BioConnect Conference
AI Summary
Milestone Pharmaceuticals Inc. announced that its management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, in New York. A live webcast of the fireside chat will be available to conference participants on May 19th at 3:00pm ET, with a replay accessible for approximately 90 days on the company's website. Milestone Pharmaceuticals is focused on developing innovative cardiovascular medicines, with its lead product, CARDAMYST (etripamil) nasal spray, being FDA-approved for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT).
Key Highlights
- Milestone Pharmaceuticals management to present at the H.C. Wainwright 4th Annual BioConnect Investor Conference.
- The presentation will take place on Tuesday, May 19, 2026, in New York.
- A live webcast of the fireside chat will be available on May 19th at 3:00pm ET.
- The webcast replay will be accessible for approximately 90 days on Milestone's website.
- Milestone Pharmaceuticals is a biopharmaceutical company developing cardiovascular medicines.
- Its lead product, CARDAMYST (etripamil) nasal spray, is FDA-approved for PSVT.
Price Impact
More from MIST